Vaxart Revenue and Competitors
Estimated Revenue & Valuation
- Vaxart's estimated annual revenue is currently $4.2M per year.
- Vaxart received $18.4M in venture funding in January 2015.
- Vaxart's estimated revenue per employee is $34,090
- Vaxart's total funding is $52.7M.
Employee Data
- Vaxart has 122 Employees.
- Vaxart grew their employee count by -22% last year.
Vaxart's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Assistant to CEO | Reveal Email/Phone |
2 | President, CEO and Director | Reveal Email/Phone |
3 | Chief Medical Officer (CMO) | Reveal Email/Phone |
4 | SVP, Technical Operations | Reveal Email/Phone |
5 | VP, Business Strategy and Planning | Reveal Email/Phone |
6 | VP Clinical Operations | Reveal Email/Phone |
7 | VP Regulatory Affairs | Reveal Email/Phone |
8 | SVP and General Counsel | Reveal Email/Phone |
9 | VP, Analytical Development | Reveal Email/Phone |
10 | VP and Head Human Resources | Reveal Email/Phone |
Vaxart Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11830M | 8030 | 26% | $2.7B | $83B |
#2 | $7.5M | 68 | 13% | $51.4M | N/A |
#3 | $1200M | 1330 | -6% | $2.4B | $8.4B |
#4 | $18.6M | 120 | 2% | N/A | N/A |
What Is Vaxart?
Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. The lead programs are prophylactic oral vaccines for seasonal influenza, RSV and norovirus, as well as a therapeutic vaccine for HPV types 16 and 18. Vaxart vaccines are convenient room temperature-stable tablets that are easy to administer, and that eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. The company is listed on the NASDAQ exchange under ticker nymbol VXRT.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$52.7M
Total Funding
122
Number of Employees
$4.2M
Revenue (est)
-22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vaxart News
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.
First, it is an oral vaccine. Vaxart prides itself...
Vaxart ( VXRT -0.22% ) and Moderna ( MRNA -1.70% ) have a lot in common. Both companies are working on coronavirus vaccines, and both claim...
SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced the addition of Julie M. Cherrington, Ph.D., to the company's board of directors. Dr. Cherrington is an experienced life science executive with extensive insights into taking drugs through the ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35.6M | 128 | 16% | $226.1M |
#2 | $35.1M | 130 | 7% | N/A |
#3 | $26.9M | 131 | 10% | N/A |
#4 | $35.4M | 131 | 28% | $239.8M |
#5 | $21.2M | 137 | -26% | $110M |
Vaxart Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2007-11-16 | $3.3M | A | Quantum Technology Partners, Life Science Angels | Article |
| 2010-03-05 | $12.5M | B | Care Capital of Princeton NJ | Article |
| 2013-08-07 | $20.0M | C | Article | |
| 2015-01-09 | $18.4M | Undisclosed | Care Capital | Article |